CONTENTS

<table>
<thead>
<tr>
<th>Name of content</th>
<th>Page no</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of Abbreviations</td>
<td>I</td>
</tr>
<tr>
<td>List of Equipments</td>
<td>III</td>
</tr>
<tr>
<td>List of Chemicals</td>
<td>IV</td>
</tr>
<tr>
<td>List of Figures</td>
<td>V</td>
</tr>
<tr>
<td>List of Tables</td>
<td>VIII</td>
</tr>
<tr>
<td>List of Photomicrographs</td>
<td>IX</td>
</tr>
</tbody>
</table>

1. Introduction
   1.1 Background........................................................................01
      1.1.1 Oral Bioavailability...................................................03
      1.1.2 Intestinal absorption process........................................04
      1.1.3 Categories of Bioavailability problems................................05
      1.1.4 Intestinal permeation enhancers........................................06
   1.2 Delivery systems...................................................................11
   1.3 Nonionic surfactant based delivery systems............................13
      1.3.1 Vesicular systems..........................................................14
         1.3.1.1 Classification of vesicular systems...............................19
         1.3.1.2 Mechanism of uptake of niosomes..................................19
         1.3.1.3 Modified non ionic surfactant vesicles..........................26
         1.3.1.4 Biomedical and Therapeutic applications--------------------30
      1.3.2 Microemulsion..................................................................31
         1.3.2.1 Surfactants................................................................33
         1.3.2.2 Phase behavior in a surfactant system..........................33
   1.4 Toxicity and Stability..........................................................38
   1.5 Drug profile...........................................................................41
   1.6 Analytical methods of Cyclosporine........................................47
   1.7 Research Envisaged and Rationale for proposed delivery.............50
   1.8 Objectives..............................................................................52
   1.9 Plan of work...........................................................................53

2. Preformulation, Analytical method development and partial validation of method for CsA
   2.0 Preformulation studies...........................................................56
   2.1 Methods employed.....................................................................56
   2.2 Drug Excipient interaction studies..........................................57
   2.3 Development of Analytical method for estimation of CsA in solvent and blood...58
   2.4 Apparatus and Chromatographic conditions..................................59
   2.5 Results and Discussion...........................................................60
3. Formulation development and characterization

3.1 Development of nonionic surfactant based formulations bearing cyclosporine

3.1 Preparation of surfactant vesicles

3.2 Preparation of bilosomes

3.3 Optimization of Process Variables

3.4 Characterization of vesicles

3.5 Preparation of granular Proniosomes

3.6 Sandimmune-Neoral (Marketed formulation)

3.7 Results and Discussion

3.8 Microemulsions

3.9 Results and Discussion

3.9.4 Thermodynamic Stability studies

4. In Vitro Performance Evaluation of formulations bearing CsA

4.0 Intestinal absorption

4.2.1 Animals

4.2.2.1 In vitro everted gut sac technique

4.2.2.2 In-situ method of drug absorption

4.2.3 Parameters used in intestinal absorption studies

4.3 Effect of formulations bearing CsA on Lymphocyte proliferation

4.4 Results and Discussion

5. In vitro toxicity studies

5.0 In vitro toxicity studies

5.1 Intestinal perfusion

5.2 Lactate dehydrogenase assay

5.3 Histology

5.5 Results and Discussion

6. In Vivo studies

6.0 In-vivo studies

6.1 Animals

6.1.1 Bioavailability study

6.1.2 Experimental Design

6.2 Results and Discussion

Summary and Conclusion

References

List of Patents and Publications

Jawaharlal Nehru University (Central Drug Research Institute)